2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Chau T. Dang, MD, discusses the rationale of the phase 2 BERENICE trial in early-stage HER2-positive breast cancer.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Chau T. Dang, MD, medical oncologist, the Regional Care Network Medical Site Director,Memorial Sloan Kettering Westchester, discusses the rationale of the phase 2 BERENICE trial (NCT02132949) in early-stage HER2-positive breast cancer.
The BERENICE trial was a multicenter, 2-cohort study that utilized the primary end of cardiac safety, Dang says. Patients in cohort A received dose-dense anthracycline-based chemotherapy followed by pertuzumab (Perjeta), trastuzumab (Herceptin), and paclitaxel, Dang explains. In cohort B, patients received 5-fluorouracil, epirubicin, and cyclophosphamide, followed by docetaxel, trastuzumab, and pertuzumab, Dang says.
Moreover, the secondary end points of the study included total pathologic complete response rate, event-free survival, invasive disease-free survival, and overall survival, Dang concludes.
Related Content: